(myeloid) (lymphoid) (unknown)

FIGURE 3 Phase II nilotinib response in imatinib-resistant/imatinib-intolerant chronic myelogenous leukemia (CML) patients. Phase II results showing percent of patients in each phase of CML. Chronic phase, accelerated phase, blast crisis (BC)-myeloid, BC-lymphoid, and BC-unknown) with complete and partial cytogenetic responses. Abbreviations: AP, accelerated phase; BC, blast crisis; CCyR, complete cytogenetic response; CML, chronic myelogenous leukemia; CP, chronic phase; PCyR, partial cytogenetic response.

(7% grade 1 or 2 and 7% grade 3 or 4), increased lipase (5% grade 3 or 4), and increased AST and/or ALT (1% grade 1 or 2 and 3% grade 3 or 4) (25). The frequency and grade of bilirubin elevations increased with nilotinib dose, but these rises were generally self-limiting and resolved with continued dosing of nilotinib (25). Analysis of ECGs indicated one instance of increased QTcF (5-15 msec). One patient had two treatment-related adverse cardiac events (grade 1 pericardial effusion and grade 2 atrial fibrillation) (25).

In the open-label phase II trial of nilotinib, adverse events that occurred in >10% of patients with CML included thrombocytopenia (32%), headache (29%), fatigue (29%), nausea (28%), pruritus (27%), rash (27%), anemia (26%), diarrhea (25%), neutropenia (21%), vomiting (20%), muscle spasms (20%), constipation and arthralgia (17% each), bone pain, myalgia, and peripheral edema (13% each), and abdominal pain and dyspepsia (12% each) (26-28).

Was this article helpful?

0 0
Constipation Prescription

Constipation Prescription

Did you ever think feeling angry and irritable could be a symptom of constipation? A horrible fullness and pressing sharp pains against the bladders can’t help but affect your mood. Sometimes you just want everyone to leave you alone and sleep to escape the pain. It is virtually impossible to be constipated and keep a sunny disposition. Follow the steps in this guide to alleviate constipation and lead a happier healthy life.

Get My Free Ebook

Post a comment